



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009

Kos Pharmaceuticals, Inc

[View the current Kos Pharmaceuticals, Inc Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/25376-Kos+Pharmaceuticals%2C+Inc.html)

(<http://www.bioportfolio.com/biocorporate/25376-Kos+Pharmaceuticals%2C+Inc.html>)

Contact Details:

**1 Cedar Brook Drive
Cranbury
New Jersey
08512-3618
United States of America**

Tel: 609-495-0500
Fax: 609-495-0920
Email:

Kos Pharmaceuticals, Inc. ("Kos" or the "Company") – named after the Greek island where Hippocrates founded the science of medicine – is a fully integrated specialty pharmaceutical company engaged in the development of proprietary prescription pharmaceutical products, principally for treatment of cardiovascular, respiratory and metabolic diseases. The Company’s principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, effectiveness and patient compliance.

Press Releases on Kos Pharmaceuticals, Inc:

Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	<i>EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25</i>
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	<i>/PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper</i>

[iThemba Pharmaceuticals \(Pty\) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering](#) 25th November, 2009

DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals and Pyxis Discovery announced today that they have signed a collaborative agreement

NEW YORK, Nov. 25 /PRNewswire/ --

[Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective](#) 25th November, 2009 Reportlinker

Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective <http://www>

NEW YORK, Nov. 25 /PRNewswire/ --

[Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis](#) 25th November, 2009 Reportlinker

Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis <http://www>

Kos Pharmaceuticals, Inc Patents:



- 7309606- [Methods and compositions for treating hypercholesterolemia](#)
- 5855884- [Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker](#)
- 6020305- [Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors](#)
- 6155251- [Breath coordinated inhaler](#)
- 6406715- [Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles](#)
- 6491950- [Controlled release pharmaceutical composition](#)
- 6676967- [Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia](#)
- 6746691- [Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics](#)
- 6818229- [Intermediate release nicotinic acid compositions for treating hyperlipidemia](#)
- 7011848- [Hydrophobic component free sustained release nicotinic acid compositions for treating](#)

[hyperlipidemia and related methods therefor](#)

- 7056494- [Method of treating a systemic disease](#)
- 7056957- [Formation of strong superporous hydrogels](#)
- 5250529- [Method alleviating migraine headache with mast cell degranulation blocking agents](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

